Dacarbazine drug data and news

---

International Approvals: Alertec, Multiferon, Alvesco  Feb 27, 2006
...for a natural human alpha-interferon injection, allowing its use for the adjuvant treatment of high-risk melanoma after excision and dacarbazine therapy; and ... - Medscape (subscription)

Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft ...  Mar 3, 2006
All were scheduled to receive neoadjuvant concomitant radiotherapy and chemotherapy with MAID (mesna, ifosfamide, doxorubicin and dacarbazine). ... - Cancer Consultants (press release),

Viragen's Multiferon Approved in Sweden for First-Line Adjuvant ...  Feb 21, 2006
...natural human alpha interferon) for the first-line adjuvant treatment of high-risk (Stages IIb- III) malignant melanoma following dacarbazine (DTIC) after ... - DG News

Viragen's Multiferon approved in Sweden  Feb 22, 2006
...regulators have approved Viragen's Multiferon for the first-line adjuvant treatment of high-risk malignant melanoma following dacarbazine after surgical ... - Pharmaceutical Business Review

Neoadjuvant Sarcoma Chemotherapy Results in High Toxicity Levels  Mar 1, 2006
The patients received three cycles of neoadjuvant modified mesna, doxorubicin, ifosfamide and dacarbazine (MAID), interdigitated radiotherapy and following ... - Cancerpage.com,

Bilateral adrenal masses: phaeochromocytoma or melanoma?  Feb 28, 2006
Despite replacement steroids and a course of palliative dacarbazine chemotherapy, the patient died 9 months after first detection of the adrenal masses. ... - Journal of the Royal Society of Medicine

Genasense(R) New Drug Application Accepted for Review by FDA  Mar 1, 2006
Genta has also filed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - Yahoo! News (press release)

Randomized Trial Shows Ganite(R) Effective When Compared with a ...  Mar 2, 2006
Genta has also submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire (press release),

Metastatic Melanoma Responds to Taxol® and Paraplatin®  Feb 16, 2006
Metastatic melanoma responds poorly to chemotherapy with the main drugs being temozolomide or dacarbazine after failure of immunotherapy or vaccination. ... - Cancer Consultants (press release),

Results show Genta's cancer drug is effective  Feb 3, 2006
The phase III study randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or without Genasense (oblimersen). ... - Pharmaceutical Business Review

Patients With Newly Diagnosed Glioblastoma Multiforme - Health ...  Feb 6, 2006
TEMODAR Capsules are contraindicated in patients who have a history of hypersensitivity to any of its components, or to dacarbazine (DTIC). ... - Medical News Today (press release),

International Approvals: Cubicin and Temodal  Feb 6, 2006
Temozolomide is contraindicated in patients with a history of hypersensitivity to dacarbazine and should be used with caution in those with severe hepatic or ... - Medscape (subscription)

Genasense(R) Marketing Authorization Application in Melanoma ...  Feb 1, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, particularly for patients for ... - PR Newswire (press release),

Analysis of Genasense(R) Trial Confirms Major Efficacy Variables ...  Feb 2, 2006
...randomized trial ever conducted in patients with advanced melanoma -- randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or ... - PR Newswire (press release),

Garden State Business Briefs  Feb 2, 2006
The clinical trial involved 771 patients with advanced melanoma. Some were given treatment with Genasense and dacarbazine, an intravenous form of chemotherapy. ... - Newark Star Ledger,

Highlights of rising and falling US stocks  Feb 2, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, the Berkeley Heights, NJ-based ... - Investor's Business Daily (subscription)

No Information Provided.